Prominent publications by Junqi Niu

KOL Index score: 17158

BACKGROUND & AIMS: There is no satisfactory way to identify patients who will maintain a response after discontinuation of nuleos(t)ide analogue therapy for chronic hepatitis B virus (HBV) infection. We investigated whether patients with negative results from tests for HBV DNA and HBV RNA (double negative) at the end of treatment maintain a long-term response to treatment.

METHODS: We performed a post-hoc analysis of data from a 2-year multi-center randomized controlled trial, and its ...

Known for Hbv Dna |  Clinical Relapse |  Negative Patients |  Antigens Hepatitis |  Rna Treatment
KOL Index score: 12207

BACKGROUND AND AIM: The prevalence of the hepatitis B virus (HBV) is higher in adults than in children. We determined the seroepidemiology of HBV infection in an adult population in JiLin, China, to guide effective preventive measures.

METHODS: A cross-sectional serosurvey was conducted throughout JiLin, China. A total of 3833 people was selected and demographic and behavioral information gathered. Serum samples were tested for HBV markers and liver enzymes.

RESULTS: The prevalence of ...

Known for Northeast China |  Hbv Infection |  Independent Predictors |  Antigens Hepatitis |  Adult Population
KOL Index score: 12034

AIMS: We aimed to develop new simple predictive models for significant fibrosis and inflammation in chronic hepatitis patients using routine laboratory parameters.

METHODS: A total of 218 patients who had undergone liver biopsy were enrolled in our study. Among these, 116 had chronic hepatitis B, 65 had primary biliary cirrhosis, and 37 had autoimmune hepatitis. Patients were divided into two groups: absent-mild (S0-S1, G0-G1) and moderate-severe (S2-S4, G2-G4) according to the ...

Known for Chronic Hepatitis |  Liver Fibrosis |  Blood Cell |  Distribution Width |  Sensitivity Specificity
KOL Index score: 10572

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.

METHODS: A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 ...

Known for Chronic Hepatitis |  Amap Score |  Hcc Risk |  Hepatocellular Carcinoma |  Development Patients
KOL Index score: 6777

Objective To investigate the clinical effect and safety of long-acting pegylated interferon-α-2b (Peg-IFN-α-2b) (Y shape, 40 kD) injection (180 μg/week) in the treatment of HBeAg-positive chronic hepatitis B (CHB) patients, with standard-dose Peg-IFN-α-2a as positive control. Methods This study was a multicenter, randomized, open-label, and positive-controlled phase III clinical trial. Eligible HBeAg-positive CHB patients were screened out and randomized to Peg-IFN-α-2b (Y shape, 40 ...

Known for Chronic Hepatitis |  Pegylated Interferon |  Hbeag Positive |  48 Weeks |  Chb Patients
KOL Index score: 6102

The transcription factor forkhead box P3 (FOXP3) is essential for the development of regulatory T cells (Tregs) and their function in immune homeostasis. Previous studies have shown that in natural Tregs (nTregs), FOXP3 can be regulated by polyubiquitination and deubiquitination. However, the molecular players active in this pathway, especially those modulating FOXP3 by deubiquitination in the distinct induced Treg (iTreg) lineage, remain unclear. Here, we identify the ubiquitin-specific ...

Known for Treg Function |  Foxp3 Degradation |  Immune Homeostasis |  Regulatory Cells |  Forkhead Transcription
KOL Index score: 5844

Background and aimLong-term treatment with tenofovir disoproxil fumarate (TDF) has demonstrated suppression of viral replication outside of China. This study aims to assess efficacy, resistance and safety of TDF for up to 240 weeks in Chinese patients with chronic hepatitis B virus (HBV) infection.MethodsPatients (HBeAg-positive or HBeAg-negative) who were randomised to receive TDF 300 mg or adefovir dipivoxil (ADV) 10 mg once daily in the 48-week double-blind phase (N = 498) were ...

Known for Chronic Hepatitis |  Tenofovir Disoproxil Fumarate |  Patients Tdf |  Hbv Infection |  Viral Replication
KOL Index score: 5426

BACKGROUND: Obesity is typically associated with metabolic dysfunction, but its impact on hepatocellular carcinoma (HCC) remains unclear in patients with chronic hepatitis B (CHB).

AIM: To study the effect of obesity on HCC development in patients with CHB receiving antiviral therapy.

METHODS: We included patients from a Chinese multicentre, prospective, observational, treated CHB cohort in this study. General obesity was evaluated by body-mass index (BMI). Central obesity was evaluated ...

Known for Central Obesity |  Chronic Hepatitis |  Hepatocellular Carcinoma |  Hcc Patients |  Liver Neoplasms
KOL Index score: 5128

Alpha-fetoprotein (AFP), as the most widely used biomarker of hepatocellular carcinoma (HCC), was correlated with ongoing liver damage. The aim of this study was to evaluate the ability of inflammatory correction-based AFP to identify HCC from other liver diseases.From March 2012 to March 2017, among 926 participants, a total of 501 patients whose transaminases were higher than the upper limit of normal range, including 166 treatment-naïve HCC patients were enrolled in our retrospective ...

Known for Hepatocellular Carcinoma |  Afp Hcc |  Hepatitis Virus |  Liver Diseases |  Biomarkers Tumor
KOL Index score: 744

Objective To explore the related factors for primary hepatic carcinoma (PHC) caused by chronic hepatitis B (CHB) and hepatitis C (CHC). Methods According to the principle of cross-sectional study, a cluster random sample method was used, a total of 366 chronic hepatitis patients in hospitals were recruited from three provincial tertiary hospitals in Shanxi, Henan and Jilin between July 2016 and October 2016, respectively. Using a self-designed unified questionnaire, face-to-face ...

KOL Index score: 117
Known for Hepatocellular Carcinoma


Junqi Niu: Influence Statistics

Sample of concepts for which Junqi Niu is among the top experts in the world.
Concept World rank
height hcc development #6
hcc risk height #6
hcc development bmi #6
hcc central obesity #6
height hcc #6
central obesity height #14
chb bmi #30
obesity hcc development #37
hcc central #44
rdw clinical #45
evaluated waist #48
patients hbv rna #54
patients central obesity #57
chb antiviral therapy #63
male albumin #66
platelets amap #67
donafenib #68
foxp3 degradation #69
amap risk #71
amap risk score #80
chinese society hepatology #91
hbv dna rna #96
relapse hbv #96

Key People For Chronic Hepatitis

Top KOLs in the world
Patrick Marcellin
chronic hepatitis adefovir dipivoxil hcv genotype
Michael Peter Manns
chronic hepatitis liver transplantation hepatocellular carcinoma
Anna Shuk‐Fong Lok
chronic hepatitis hepatocellular carcinoma united states
Stefan S Zeuzem
chronic hepatitis hcv genotype liver fibrosis
Jay H Hoofnagle¶¶
chronic hepatitis liver injury united states
Zachary D Goodman
chronic hepatitis liver fibrosis hepatocellular carcinoma

Junqi Niu:Expert Impact

Concepts for whichJunqi Niuhas direct influence:Chronic hepatitis,  Hbv dna,  Central obesity,  Hepatocellular carcinoma,  Primary liver cancer,  Chronic hepatitis patients,  Antiviral therapy,  Hepatocellular carcinoma hcc.

Junqi Niu:KOL impact

Concepts related to the work of other authors for whichfor which Junqi Niu has influence:Chronic hepatitis,  Hbv rna,  Hepatocellular carcinoma,  Amap score,  Liver fibrosis,  Hbsag loss,  Hcc patients.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Department of Hepatology, Center of Infectious Disease and Pathogen Biology, Key laboratory of Organ Regeneration and Transplantation of the Ministry of Education, State Key Laboratory of Zoonotic Disease, The First Hospital of Jilin University, Chan

FREE Custom List